Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

This study has suspended participant recruitment.
(Scheduled interim monitoring)
Sponsor:
Collaborator:
Exelixis
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01811212
First received: March 12, 2013
Last updated: July 4, 2016
Last verified: July 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)